Therapeutic area intelligence for JAK2 Inhibition with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Eli Lilly →

Assets

No related entities indexed yet.

Recent signals(1)

CompetitiveJuly 21, 2026

Lilly to acquire Ajax Therapeutics for myelofibrosis and polycythemia vera

Lilly is acquiring Ajax Therapeutics to enhance its portfolio in treating myelofibrosis and polycythemia vera, leveraging Ajax's lead program, AJ1-11095, a first-in-class Type II JAK2 inhibitor.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.